NCT03040986View on ClinicalTrials.gov

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

August 10, 2018

Study Completion Date

October 15, 2020

Conditions
KRAS NP_004976.2:p.G12RStage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Selumetinib Sulfate

Given by mouth (PO)

Trial Locations (9)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20892

NCI - Center for Cancer Research, Bethesda

27710

Duke University Medical Center, Durham

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

48201

Wayne State University/Karmanos Cancer Institute, Detroit

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03040986 - Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations | Biotech Hunter | Biotech Hunter